Asymptomatic hyperuricaemia (AH) is an independent risk factor for chronic kidney disease, cardiovascular events, and metabolic disorders. However, controversies persist regarding the clinical use of
Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.
Randomized controlled trials (RCTs) have assessed the efficacy of anti-programmed cell death 1 (PD- 1)/programmed cell death ligand 1 (PD-L1), alone or combined with other therapies, for ovarian cance
